Drug Delivery: What The Future Holds - - BioPharm International


Drug Delivery: What The Future Holds

BioPharm International
Volume 20, Issue 8

It can be argued that nanotechnology has already affected drug delivery. Submicron particles of poorly soluble drugs are currently being used to "solubilize" drugs to enhance oral bioavailability. Three products using such technology are on the market with sales of over $1 billion: Tricor (fenofibrate) tablets, Rapamune (sirolimus) tablets, and Emend (aprepitant) capsules. The approach will likely be used for injectable suspensions as well.


The number of gene-therapy clinical trials that have been conducted is now over 1,000.27 However, success to date is fairly limited. Significant challenges exist for gene delivery systems, including avoiding the immune system and efficiently transferring the gene to the nucleus of the target cell. If an efficient delivery system for gene delivery can be developed, it has the potential to revolutionize treatment paradigms, particularly for inherited, malignant, and infectious diseases.


The visibility of vaccines has significantly increased due to efforts to combat bioterrorism, drug-resistant bacteria, cancer, and viral diseases. Advances in today's vaccines include the use of recombinant proteins, DNA, and genetically-modified toxins.While aluminum hydroxide remains one of the most-used adjuvants for injectable vaccines, new adjuvant systems such as the saponin QS-21, and MF-59, a squalene-based emulsion, are now available.

Better adjuvants coupled with efficient delivery systems have the potential to enhance the effectiveness of vaccines.28–30 This is particularly critical in the case of cancer vaccines. Not only are patients often immunocompromised, but tumor antigens are often poorly immunogenic, and tumor escape mechanisms exist (e.g., secretion of suppressive cytokines).31,32 Thus, adjuvants for cancer vaccines may need to be more toxic than prophylactic adjuvants. The ideal vaccine delivery system would not only intensify the immune response, but would also provide an optimized exposure profile (e.g., prolonged or pulsatile release).


Kola and Landis reviewed success rates over the last decade for various classes of compounds gaining approval after having reached initial clinical trials.33 Drugs for oncology and central nervous system (CNS) diseases have two of the lower success rates (less than 10%, as shown in Figure 4). [Editors note: Figures for this article are not available online. To obtain a complete copy of the article with figures, please send your mailing address to
]. While there are a number of factors involved, the failures in drug delivery to tumors and the CNS can be attributed at least partly to the drugs not reaching the target efficiently.

Treating cancer has long been aimed at selectively targeting the tumor while sparing normal tissue. Two approaches to cancer targeting are physical methods and specific binding. Enhanced permeability and retention is an example of physical targeting. Tumor vasculature is generally leakier than normal vasculature, allowing particles such as liposomes and macromolecules to extravasate and reach the tumor in higher concentrations than in normal tissue.34,35 Accumulation at the desired site is further enhanced because lymphatic vessels do not form in tumors, so that the extracellular material is not drained as in normal tissue.

Antibody-based therapeutics, such as Herceptin and antibody-conjugated delivery systems, are examples of specific binding targeting. Recent advances in humanized antibodies have facilitated advances in this area.36 The use of specific antibodies to treat patient subpopulations is a key area in personalized medicine.37 By attaching nanoparticles or liposomes to antibodies, it is possible to specifically target the dose to the appropriate site of action.38, 39


It seems appropriate to end by discussing drug delivery to that most complex of organs, the brain. As noted above, success rates for CNS drugs have been low. In contrast to tumor vasculature, the capillaries of the the blood-brain barrier (BBB) are characterized by tightly packed endothelial cells held firm by tight junctions.40 In general, this limits passive diffusion to small, highly lipophilic molecules. Even if a drug can permeate the membrane, the BBB has effective efflux mechanisms. Due to these restrictions, nearly 100% of large-molecule and greater than 98% of small-molecule drugs do not cross the BBB.41

blog comments powered by Disqus



Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here